Located at HIPRA’s Campus in Aiguaviva, the new Bacterial Culture Unit (CB6) is a facility equipped with state-of-the-art technologies that will enhance the company's production infrastructure with the aim of boosting the development and manufacturing of biotechnological vaccines. 

This new project, framed within the company’s industrial and technological growth strategy, represents an investment of over 26 million euros. The initiative has been supported by the Department of Business and Labour of the Government of Catalonia and by ACCIÓ, through the grant scheme aimed at reindustrialisation and promoting new industrial investments in the region.

CB6 is a production unit focused on animal and human health, specialising in the production of antigens (the active ingredient of vaccines) and recombinant proteins, obtained through microbial systems such as bacteria, mycoplasmas, and yeasts. This facility also includes processes for obtaining and purifying substances generated by these microorganisms. The building covers a total area of 5,570 m² and operates under a BSL2+ biosafety level. 

With this step, HIPRA reaffirms its commitment to innovation and technological expansion to consolidate its leadership in the animal and human health sectors.

With the support of: